Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fontan Udenafil Exercise Longitudinal Assessment Trial (FUEL)

Next Previous
Trial Profile

Fontan Udenafil Exercise Longitudinal Assessment Trial (FUEL)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Udenafil (Primary)
  • Indications Congenital heart defects; Ventricular dysfunction
  • Focus Registrational; Therapeutic Use
  • Acronyms FUEL
  • Sponsors Mezzion

    • Most Recent Events

    • 30 Oct 2023 Results evaluating the effects of udenafil on vital signs, published in the American Journal of Cardiology
    • 21 Dec 2021 According to a Mezzion media release, new data from its Phase 3 efficacy and safety trial (FUEL Trial) and its open label extension trial (FUEL OLE Trial) was presented to the U.S. Food and Drug Administration (FDA) in a Type C meeting held on December 16, 2021.
    • 25 May 2021 According to a Mezzion Pharma media release, The FDA also advised in the FDA Notice that the FDA is not currently planning to hold an advisory committee meeting to discuss Mezzion's NDA.Company fully expects that, upon FDA approval of its NDA for the treatment of SVHD patients, a rare pediatric disease, it will be awarded a PRV, at which time the PRV will be fully redeemable and/or transferrable.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top